StockPriceToday
Ultragenyx Pharmaceutical Inc. (RARE)
About Ultragenyx Pharmaceutical Inc.
Ultragenyx Pharmaceutical Inc., founded in 2010, has rapidly established itself as a leader in rare disease drug development with a mission to bring novel therapies to patients with serious genetic diseases. The company's name reflects its focus on ultra-rare conditions where patients often have no treatment options. RARE stock price reflects the company's successful track record of bringing multiple products to market and its continued pipeline advancement.
Led by founder and CEO Emil Kakkis, MD, PhD, who previously founded and led another successful rare disease company, Ultragenyx benefits from visionary leadership with deep expertise in rare disease drug development. The management team combines scientific excellence with proven commercial execution capabilities, having successfully launched multiple products globally. Leadership's strategic focus on building a sustainable rare disease company with diversified revenue streams has been instrumental in creating shareholder value and driving RARE stock price appreciation.
Ultragenyx operates as a fully integrated biopharmaceutical company with approved products generating revenue while continuing to invest in pipeline expansion. The company's commercial portfolio includes treatments for rare metabolic, bone, and genetic diseases, with additional programs in clinical development. With proven ability to develop and commercialize rare disease therapies, multiple revenue-generating products providing financial sustainability, and a robust pipeline offering continued growth potential, RARE represents an attractive investment in the high-value rare disease sector where successful treatments command premium pricing and benefit from market exclusivity.
RARE Stock 12 Month Chart
Latest News for RARE
Ultragenyx Pharmaceutical reported Q3 2026 revenue of US$173 million and a net loss of US$118 million, while securing FDA approval and first commercial launches for its gene therapies GENGLYCOS and ...
Ultragenyx Pharmaceutical has seen its stock lose ground over several years even as new rare disease treatments and regulatory decisions continue to reshape its outlook. With the share price recently ...
Ultragenyx Pharmaceutical stock was hit with a flurry of downgrades after the biotech’s rare-disease drug candidate failed to meet its main goal in a late-stage trial. Still, some analysts believe the ...
Other Popular Stocks
T. Rowe Price Group Inc. (TROW) is a leading global investment management firm providing mutual funds, institutional investment services, and retirement plan services to...
TriCo Bancshares (TCBK) is a bank holding company operating Tri Counties Bank, providing commercial and retail banking services throughout Northern and Central California with...
Golub Capital BDC Inc. (GBDC) is a business development company that invests primarily in senior secured loans of middle-market companies.